Related Experiment Video
Updated: Aug 17, 2026

Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
Published on: August 24, 2016
Fosfructose (Questcor)
1Department of Physiology, Northeastern Ohio Universities College of Medicine, 4209 State Route 44, PO Box 95, Rootstown, OH 44272-0095, USA. hgfokes@neoucom.edu
Abstract:
Fosfructose is a cytoprotective natural sugar phosphate under development by Questcor (formerly Cypros) for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions. It is in phase III trials for sickle cell anemia [309234] and is in phase II/III trials for cardiovascular ischemia resulting from bypass surgery [337683]. The company has also commenced preclinical trials of fosfructose for asthma [337683]. In September 1999, the FDA granted fosfructose Fast Track designation for the treatment of the acute complications associated with coronary artery bypass graft surgery [340368].
Related Concept Videos
Glycolysis: Preparatory Phase
Fats as Energy Storage Molecules
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...

